IP Library › Granted Patent US 10,646,465
Granted Patent B2
US 10,646,465 · App. 16/063,278 · Granted May 12, 2020

Small molecules against cancer

Inventors: Amnon Peled (Tel-Aviv, IL); Michal Abraham (Mevasseret Zion, IL); Orly Eizenberg (Rechovot, IL)
Assignee: Biokine Therapeutics Ltd.
A61K31/352A61K31/167A61K31/192A61K31/341A61K31/366A61K31/37A61K31/661A61K45/06A61P35/00C07D215/26C07D311/76C07D401/12C07D405/12C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,646,465
App. No.
16/063,278
Granted
May 12, 2020
Kind
B2
Abstract

Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.

Claims (4)

1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a compound having the formula:

thereby treating the cancer, wherein said cancer is selected from the group consisting of a leukemia, a lymphoma and a lung cancer.

2. The method of claim 1 , further comprising administering to the subject an additional anti-cancer agent.

3. The method of claim 1 , wherein treating said cancer is by increasing a level of hematopietic stem cells in peripheral blood of the subject, the method further comprising obtaining hematopietic stem cells from peripheral blood of the subject, administering a cytotoxic therapy to the subject, and transplanting said stem cells back into the subject subsequent to said cytotoxic therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2022
From: BIOKINE THERAPEUTICS LTD.
To: ALONBIO LTD.
Reel/Frame 059042/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2018
From: PELED, AMNON; ABRAHAM, MICHAL; EIZENBERG, ORLY
To: BIOKINE THERAPEUTICS LTD.
Reel/Frame 046277/0029 →
Continuity (4)
Provisional Application 62268568 · Dec 17, 2015
Provisional Application 62268575 · Dec 17, 2015
Provisional Application 62268579 · Dec 17, 2015
Related Publication 20190240188A1 · Aug 8, 2019
Cited By (2)
US 12,202,803 US 12,233,057